The Centers for Disease Control and Prevention has released evidence-based recommendations to prevent and control Staphylococcus aureus in neonatal intensive care units, including strains resistant (MRSA) or sensitive (MSSA) to the antibiotic methicillin.

The recommendations supplement existing CDC recommendations for all health care settings based on a systematic review of the best available literature, the agency said.

“While MRSA has long been the focus of prevention efforts due to the difficulty in treating and eradicating it, recent studies have demonstrated that methicillin-sensitive S. aureus (MSSA) has morbidity and mortality equal to MRSA and occurs more frequently in NICU patients,” the guidelines note.

Related News Articles

Headline
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…
Headline
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
There have been 8,064 reported cases of whooping cough in the U.S. so far this year, according to the latest data from the Centers for Disease Control and…
Headline
A study published April 17 by BMC Infectious Diseases found increased incidents of Acinetobacter baumannii and carbapenem-resistant A. baumannii infections…
Headline
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…
Headline
The incidence of invasive group A strep infections increased from 3.6 to 8.2 cases per 100,000 people from 2013 to 2022, according to a study authored by the…